<?xml version='1.0' encoding='utf-8'?>
<document id="21395646"><sentence text="In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype."><entity charOffset="24-33" id="DDI-PubMed.21395646.s1.e0" text="efavirenz" /><entity charOffset="38-48" id="DDI-PubMed.21395646.s1.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.21395646.s1.e0" e2="DDI-PubMed.21395646.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s1.e0" e2="DDI-PubMed.21395646.s1.e1" /></sentence><sentence text="This study aimed to test whether a pharmacokinetic simulation model could extrapolate nonclinical drug data to predict human efavirenz exposure after single and continuous dosing as well as the effects of concomitant rifampicin and further to evaluate the weight-based dosage recommendations used to counteract the rifampicin-efavirenz interaction"><entity charOffset="125-134" id="DDI-PubMed.21395646.s2.e0" text="efavirenz" /><entity charOffset="217-227" id="DDI-PubMed.21395646.s2.e1" text="rifampicin" /><entity charOffset="315-325" id="DDI-PubMed.21395646.s2.e2" text="rifampicin" /><entity charOffset="326-335" id="DDI-PubMed.21395646.s2.e3" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e0" e2="DDI-PubMed.21395646.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e0" e2="DDI-PubMed.21395646.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e0" e2="DDI-PubMed.21395646.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e0" e2="DDI-PubMed.21395646.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e1" e2="DDI-PubMed.21395646.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e1" e2="DDI-PubMed.21395646.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e1" e2="DDI-PubMed.21395646.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e2" e2="DDI-PubMed.21395646.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21395646.s2.e2" e2="DDI-PubMed.21395646.s2.e3" /></sentence><sentence text="" /><sentence text="Efavirenz pharmacokinetics were simulated using a physiologically based pharmacokinetic model implemented in the Simcypâ„¢ population-based simulator"><entity charOffset="0-9" id="DDI-PubMed.21395646.s4.e0" text="Efavirenz" /></sentence><sentence text=" Physicochemical and metabolism data obtained from the literature were used as input for prediction of pharmacokinetic parameters" /><sentence text=" The model was used to simulate the effects of rifampicin on efavirenz pharmacokinetics in 400 virtual patients, taking into account bodyweight and CYP2B6 phenotype"><entity charOffset="47-57" id="DDI-PubMed.21395646.s6.e0" text="rifampicin" /><entity charOffset="61-70" id="DDI-PubMed.21395646.s6.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.21395646.s6.e0" e2="DDI-PubMed.21395646.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s6.e0" e2="DDI-PubMed.21395646.s6.e1" /></sentence><sentence text="" /><sentence text="Apart from the absorption phase, the simulation model predicted efavirenz concentration-time profiles reasonably well, with close agreement with clinical data"><entity charOffset="64-73" id="DDI-PubMed.21395646.s8.e0" text="efavirenz" /></sentence><sentence text=" The simulated effects of rifampicin co-administration on efavirenz treatment showed only a minor decrease of 16% (95% confidence interval 13-19) in efavirenz area under the concentration-time curve, of the same magnitude as what has been clinically observed (22%)"><entity charOffset="26-36" id="DDI-PubMed.21395646.s9.e0" text="rifampicin" /><entity charOffset="58-67" id="DDI-PubMed.21395646.s9.e1" text="efavirenz" /><entity charOffset="149-158" id="DDI-PubMed.21395646.s9.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.21395646.s9.e0" e2="DDI-PubMed.21395646.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s9.e0" e2="DDI-PubMed.21395646.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21395646.s9.e0" e2="DDI-PubMed.21395646.s9.e2" /><pair ddi="false" e1="DDI-PubMed.21395646.s9.e1" e2="DDI-PubMed.21395646.s9.e1" /><pair ddi="false" e1="DDI-PubMed.21395646.s9.e1" e2="DDI-PubMed.21395646.s9.e2" /></sentence><sentence text=" Efavirenz exposure depended on CYP2B6 phenotype and bodyweight"><entity charOffset="1-10" id="DDI-PubMed.21395646.s10.e0" text="Efavirenz" /></sentence><sentence text=" Increasing the efavirenz dose during concomitant rifampicin was predicted to be most successful in patients over 50 kg regardless of CYP2B6 status"><entity charOffset="16-25" id="DDI-PubMed.21395646.s11.e0" text="efavirenz" /><entity charOffset="50-60" id="DDI-PubMed.21395646.s11.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.21395646.s11.e0" e2="DDI-PubMed.21395646.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s11.e0" e2="DDI-PubMed.21395646.s11.e1" /></sentence><sentence text="" /><sentence text="Our findings, although based on a simulation approach using limited in vitro data, support the current recommendations for using a 50 kg bodyweight cut-off for efavirenz dose increment when co-treating with rifampicin"><entity charOffset="160-169" id="DDI-PubMed.21395646.s13.e0" text="efavirenz" /><entity charOffset="207-217" id="DDI-PubMed.21395646.s13.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.21395646.s13.e0" e2="DDI-PubMed.21395646.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21395646.s13.e0" e2="DDI-PubMed.21395646.s13.e1" /></sentence><sentence text="" /></document>